牛樟芝為生長於台灣特有種牛樟樹(Cinnamomum kanehirae Hayata)上獨有之真菌,近來,人們越來越重視從天然產品中尋找藥物,牛樟芝的藥理效用逐漸受世人認可,諸如腫瘤抑制、增強免疫等,而其保健使用與治療效果必須築基於毒性劑量觀念之上。本研究以微生物回復突變性試驗法(mammalian microsome reversion assay, Ames test)針對牛樟芝萃取純化次級代謝產物-倍半萜內酯Antrocin進行致突變及抗致突變性試驗,希冀了解牛樟芝之重要成份Antrocin在使用上之安全劑量範圍及可能治療癌症效果。 本實驗以鼠傷寒沙門氏菌TA98和TA100菌株分為兩部分來測試:第一組為致突變試驗,進行安全性評估討論;第二組為抗致突變性試驗,進行功能性評估討論。在安全性評估中,Antrocin試驗最高劑量100μg/ plate對這兩個菌株的菌落數量沒有致突變作用。因此,在此劑量下同時進行Antrocin的功能性評估抗致突變性測試。 在抗致突變性試驗中,Antrocin對TA100菌株的抑制率較低,在不經肝臟酵素系統中試驗只能達到24.3%的抑制率,低於本實驗室以前對各種方法培養的樟芝提取物的研究;Antrocin對TA98菌株在不經肝臟酵素系統中試驗的抑制率為33.9%,高於本實驗室以前對各種方法培養的樟芝提取物的研究,而當加入肝臟酵素系統後,抑制率可提高至66%,具高度抗致突變能力,顯示Antrocin在抗致突變之治癌效果評估需經體內肝臟酵素之代謝才能產生。
Antrodia cinnamomea, a heart-rot wood decay fungus of stout camphor (Cinnamomum kanehirae Hayata), is an endemic fungal species in Taiwan. Recently, people are paying more and more attention to search medicines from natural products. It has been reported that many chemical components of A. cinnamomea carry functional properties like tumor suppression, immunological enhancement. However the application of these components for medical cure has to found on the knowledge of the toxic dose of these components. This research studied the mutagenicity and anti-mutagenicity of Antrocin, an extract of A. cinnamomea, via mammalian microsome reversion assay (Ames test) to find the safe dose range and to verify the anti-cancer property of Antrocin and its derived pure compounds. The TA98 and TA100 strains of Salmonella typhimurium were used to conduct Ames test. Up to 100 µg/plate of Antrocin gave no suppression effect to the number of colony multiplied of these two strains. The mutagenicity test assessing the security of Antrocin and the anti-mutagenicity test assessing the function of Antrocin were therefore tested up to this dose of 100 µg/plate. No mutagenic potential was found in the security assessment for both of TA98 and TA 100 strains. For anti-mutagenicity assessment, the inhibition rate to TA100 strain exhibited by Antrocin was weak, only up to 24.3%, if S9 was not added, lower than previous studies of this laboratory on row extract of Antrodia cinnamomea cultivated from various methods. However the inhibition rate to TA98 strain was 33.9%, higher than previous studies of this laboratory on row extract of Antrodia cinnamomea, and approximately doubled, 66%, while the liver activating enzyme S9 is present.